TR
EN
Efficacy and toxicity of everolimus plus exemestane in third and later lines treatment of hormone receptor-positive, HER2-negative metastatic breast cancer
Abstract
Aim: In daily practice, everolimus plus exemestane therapy has begun to be used in the later-lines as it has been demonstrated that treatments such as cyclin-dependent kinase (CDK) 4/6 inhibitors and fulvestrant, alone or in combination, are more effective in hormone receptor (HR)-positive metastatic breast cancer (MBC). The aim of this study is to evaluate the efficacy and toxicity of everolimus plus exemestane in the third line and later-lines on HR-positive Human Epidermal Growth Factor Receptor 2 (HER2)-negative MBC treatment with real-life data.
Methods: Patients who received everolimus plus exemestane with the diagnosis of HR-positive and HER2-negative MBC between November 2013 and March 2020 were included in this retrospective cohort study. Clinicopathological characteristics of patients and treatment related toxicities were evaluated retrospectively.
Results: The median age of the 33 patients included in the study was 59 (30-77) years. Twenty-three (69.7%) of the patients had visceral metastasis, while 10 (30.3%) had only bone metastasis. Everolimus plus exemestane was used in the third line in 22 (66.6%) patients and later-lines in 11 (33.3%) patients. The median follow-up time was 15.5 months (0.3-35.5). Median progression-free survival (PFS) and overall survival (OS) were 7.0 (5.1-9.0, 95% CI) months and 21.3 (13.4-29.2, 95% CI) months, respectively. Median PFS of patients with only bone metastasis and visceral metastasis were similar (7.2 vs 6.4 months, P=0.96).
Conclusion: Everolimus plus exemestane is an effective and tolerable treatment choice in the later-lines in the treatment of HR-positive HER2-negative MBC.
Methods: Patients who received everolimus plus exemestane with the diagnosis of HR-positive and HER2-negative MBC between November 2013 and March 2020 were included in this retrospective cohort study. Clinicopathological characteristics of patients and treatment related toxicities were evaluated retrospectively.
Results: The median age of the 33 patients included in the study was 59 (30-77) years. Twenty-three (69.7%) of the patients had visceral metastasis, while 10 (30.3%) had only bone metastasis. Everolimus plus exemestane was used in the third line in 22 (66.6%) patients and later-lines in 11 (33.3%) patients. The median follow-up time was 15.5 months (0.3-35.5). Median progression-free survival (PFS) and overall survival (OS) were 7.0 (5.1-9.0, 95% CI) months and 21.3 (13.4-29.2, 95% CI) months, respectively. Median PFS of patients with only bone metastasis and visceral metastasis were similar (7.2 vs 6.4 months, P=0.96).
Conclusion: Everolimus plus exemestane is an effective and tolerable treatment choice in the later-lines in the treatment of HR-positive HER2-negative MBC.
Keywords
References
- 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
- 2. Fragomeni SM, Sciallis A, Jeruss JS. Molecular Subtypes and Local-Regional Control of Breast Cancer. Surg Oncol Clin N Am. 2018 Jan;27(1):95-120. doi: 10.1016/j.soc.2017.08.005. PMID: 29132568; PMCID: PMC5715810.
- 3. Perou CM, Sorlie T, Eisen MB,van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.
- 4. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74. doi: 10.1073/pnas.191367098. PMID: 11553815; PMCID: PMC58566.
- 5. Spitale A, Mazzola P, Soldini D, Mazzucchelli L, Bordoni A. Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol. 2009;20:628–35.
- 6. Tang P, Wang J, Bourne P. Molecular classifications of breast carcinoma with similar terminology and different definitions: are they the same? Hum Pathol. 2008;39:506–13.
- 7. Desmedt C, Sotiriou C, Piccart-Gebhart MJ. Development and validation of gene expression profile signatures in early-stage breast cancer. Cancer Invest. 2009;27:1–10.
- 8. Iwamoto T, Pusztai L. Predicting prognosis of breast cancer with gene signatures: are we lost in a sea of data? Genome Med. 2010;2:81.
Details
Primary Language
English
Subjects
Oncology and Carcinogenesis
Journal Section
Research Article
Publication Date
June 1, 2020
Submission Date
May 30, 2020
Acceptance Date
June 16, 2020
Published in Issue
Year 2020 Volume: 4 Number: 6
APA
Yıldız, F., & Öksüzoğlu, B. (2020). Efficacy and toxicity of everolimus plus exemestane in third and later lines treatment of hormone receptor-positive, HER2-negative metastatic breast cancer. Journal of Surgery and Medicine, 4(6), 443-446. https://doi.org/10.28982/josam.745731
AMA
1.Yıldız F, Öksüzoğlu B. Efficacy and toxicity of everolimus plus exemestane in third and later lines treatment of hormone receptor-positive, HER2-negative metastatic breast cancer. J Surg Med. 2020;4(6):443-446. doi:10.28982/josam.745731
Chicago
Yıldız, Fatih, and Berna Öksüzoğlu. 2020. “Efficacy and Toxicity of Everolimus Plus Exemestane in Third and Later Lines Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer”. Journal of Surgery and Medicine 4 (6): 443-46. https://doi.org/10.28982/josam.745731.
EndNote
Yıldız F, Öksüzoğlu B (June 1, 2020) Efficacy and toxicity of everolimus plus exemestane in third and later lines treatment of hormone receptor-positive, HER2-negative metastatic breast cancer. Journal of Surgery and Medicine 4 6 443–446.
IEEE
[1]F. Yıldız and B. Öksüzoğlu, “Efficacy and toxicity of everolimus plus exemestane in third and later lines treatment of hormone receptor-positive, HER2-negative metastatic breast cancer”, J Surg Med, vol. 4, no. 6, pp. 443–446, June 2020, doi: 10.28982/josam.745731.
ISNAD
Yıldız, Fatih - Öksüzoğlu, Berna. “Efficacy and Toxicity of Everolimus Plus Exemestane in Third and Later Lines Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer”. Journal of Surgery and Medicine 4/6 (June 1, 2020): 443-446. https://doi.org/10.28982/josam.745731.
JAMA
1.Yıldız F, Öksüzoğlu B. Efficacy and toxicity of everolimus plus exemestane in third and later lines treatment of hormone receptor-positive, HER2-negative metastatic breast cancer. J Surg Med. 2020;4:443–446.
MLA
Yıldız, Fatih, and Berna Öksüzoğlu. “Efficacy and Toxicity of Everolimus Plus Exemestane in Third and Later Lines Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer”. Journal of Surgery and Medicine, vol. 4, no. 6, June 2020, pp. 443-6, doi:10.28982/josam.745731.
Vancouver
1.Fatih Yıldız, Berna Öksüzoğlu. Efficacy and toxicity of everolimus plus exemestane in third and later lines treatment of hormone receptor-positive, HER2-negative metastatic breast cancer. J Surg Med. 2020 Jun. 1;4(6):443-6. doi:10.28982/josam.745731